Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych VivasChild and adolescent psychiatry — adolescent substance use

Psych Vivas · Child and adolescent psychiatry — adolescent substance use

Adolescent substance use — structured clinical viva

Fellowship viva on adolescent substance use across cannabis/alcohol/stimulants, family interventions, dual diagnosis, harm reduction, and CAMHS–AOD disposition.

clinical1 min readVerification in progress

Target exams

FRANZCPMRCPsychABPNMD-DNB
On this page
Study tools

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
You are the CAMHS/on-call psychiatry registrar. A 16-year-old presents with daily high-THC cannabis, weekend alcohol binges, and two recent methamphetamine episodes. Parents demand residential 'boot camp'. The young person is ambivalent, has low mood and one recent episode of superficial cutting, refuses urine testing, and minimises risk. Discuss assessment (CRAFFT, private interview, dual diagnosis), substance-specific risks, family-based treatment evidence, harm reduction, concurrent care principles, disposition, and how this differs from adult AUD/OUD and adult dual-diagnosis vivas.

Interpretation

Reveal interpretationShowHide

This is a polysubstance adolescent presentation with dual mental health risk (low mood, NSSI) and parental demand for coercive residential care. Minimise neither cannabis potency/frequency nor family distress.[5][6]

Assessment framework. Confidentiality-with-safety; private interview; CRAFFT then full pattern (high-THC daily, alcohol binges, methamphetamine); dual screen (mood, self-harm, psychosis, ADHD, trauma); family monitoring capacity; school interface; toxicology as adjunct not alliance test.[1]

Evidence-based care. MI for ambivalence; family-based therapy as core psychosocial (Waldron); name MDFT (Rigter) and CYT packages; brief alcohol intervention evidence; harm reduction goals (driving, binge reduction, school) per Stockings; concurrent dual care not sequential exclusion.[2][3][4][6][7]

Family communication. Validate fear; reject pejorative "boot camp only" as first step when outpatient family work is appropriate and home is safe; escalate intensity if risk high.[7]

Pharmacotherapy context. Limited for cannabis/stimulants; if opioid OUD were present, cite Woody extended BUP/NX vs short detox — not the main pathway here.[8]

Difference from adult topics. Developmental brain context, family therapy primacy, school/Gillick/confidentiality, CAMHS–AOD interface, and youth trial evidence (CYT/MDFT/CRAFFT) rather than adult AUD pharmacotherapy algorithms.[1][2][6]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References8ShowHide
  1. [1]Knight JR, Sherritt L, Shrier LA, et al. Validity of the CRAFFT substance abuse screening test among adolescent clinic patients Arch Pediatr Adolesc Med, 2002.PMID 12038895
  2. [2]Waldron HB, Turner CW Evidence-based psychosocial treatments for adolescent substance abuse J Clin Child Adolesc Psychol, 2008.PMID 18444060
  3. [3]Rigter H, Henderson CE, Pelc I, et al. Multidimensional family therapy lowers the rate of cannabis dependence in adolescents: a randomised controlled trial in Western European outpatient settings Drug Alcohol Depend, 2013.PMID 23140805
  4. [4]Dennis M, Godley SH, Diamond G, et al. The Cannabis Youth Treatment (CYT) Study: main findings from two randomized trials J Subst Abuse Treat, 2004.PMID 15501373
  5. [5]Silins E, Horwood LJ, Patton GC, et al. Young adult sequelae of adolescent cannabis use: an integrative analysis Lancet Psychiatry, 2014.PMID 26360862
  6. [6]Stockings E, Hall WD, Lynskey M, et al. Prevention, early intervention, harm reduction, and treatment of substance use in young people Lancet Psychiatry, 2016.PMID 26905481
  7. [7]Drake RE, Mercer-McFadden C, Mueser KT, et al. Review of integrated mental health and substance abuse treatment for patients with dual disorders Schizophr Bull, 1998.PMID 9853791
  8. [8]Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial JAMA, 2008.PMID 18984887
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousAdolescent eating disorders — structured clinical vivaChild and adolescent psychiatry — eating disordersNextAdvanced critical appraisal — structured clinical vivafoundations — advanced EBM and evidence synthesis